Ranibizumab (a recombinant, humanized monoclonal antibody targeting VEGF-A), Bevacizumab (a full-size humanized monoclonal antibody targeting VEGF-A), and aflibercept (a soluble decoy receptor fusion protein)1, 2, 3, are commonly used for the treatment of CNV and macular edema. This evidence concerns the gene VEGFA and macular retinal edema.